Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML - Oellerich, Thomas; Schneider, Constanze; Thomas, Dominique; Knecht, Kirsten M.; Buzovetsky, Olga; Kaderali, Lars; Schliemann, Christoph; Bohnenberger, Hanibal; Angenendt, Linus; Hartmann, Wolfgang; Wardelmann, Eva; Rothenburger, Tamara; et al. (Nature communications, 2019)
Keywords: 13/106; 13/31; 13/89; 5-aza-2'-deoxycytidine; 60 APPLIED LIFE SCIENCES; 631/67; 692/4028; 692/53; 82/51; 82/58; 96/2; Ablation; Acute myeloid leukemia; Animals; Anticancer properties; Antimetabolites, Antineoplastic - pharmacology; Antimetabolites, Antineoplastic - therapeutic use; Azacitidine - analogs & derivatives; Azacitidine - pharmacology; Azacitidine - therapeutic use; Azacytidine; Biomarkers; Biomarkers, Tumor - metabolism; Bone marrow; Bone Marrow - pathology; Cell culture; Cell Line, Tumor; Deactivation; Decitabine - pharmacology; Decitabine - therapeutic use; DNA Methylation - drug effects; Drug Resistance, Neoplasm - drug effects; Female; Gene Expression Regulation, Leukemic - drug effects; Humanities and Social Sciences; Humans; Inactivation; Leukemia; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - pathology; Metabolites; Mice; multidisciplinary; Myeloid leukemia; Patient Selection; Patients; Primary Cell Culture; Retrospective Studies; SAM Domain and HD Domain-Containing Protein 1 - metabolism; Science; Science (multidisciplinary); Substrates; Treatment Outcome; Xenograft Model Antitumor Assays; Xenografts; Xenotransplantation